Magnesium isoglycyrrhizinate ameliorates concanavalin A-induced liver injury via the p38 and JNK MAPK pathway

References

• Liver Failure And Artificial Liver Group, C.S.O.L. Guideline for diagnosis and treatment of liver failure. Chin J Hepatol. 2018;27:18–26.
   Google Scholar
• Chen WLL. Effects of glycyrrhizin on the treatment of liver disease. Int J Digest Dis. 2006;26:106–109.
   Google Scholar
• Sarin SK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353–390.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ding J, Gou C, et al. Qingchangligan formula attenuates the inflammatory response to protect the liver from acute failure induced by d-galactosamine/lipopolysaccharide in mice. J Ethnopharmacol. 2017;201:108–116.
   PubMed Web of Science ®Google Scholar
• Ou M. Progress in pharmacology and clinical research of magnesium isoglycyrrhizinate. Chin Pharm. 2010;19:83–85.
   Google Scholar
• E.C.O.C., Expert consensus on clinical application of glycyrrhizin preparation in the treatment of liver diseases. J Clin Hepatol. 2016;32:844–852.
   Google Scholar
• Li L, Zhou J, Li Q, et al. The inhibition of Hippo/Yap signaling pathway is required for magnesium isoglycyrrhizinate to ameliorate hepatic stellate cell inflammation and activation. Biomed Pharmacother. 2018;106:83–91.
   PubMed Web of Science ®Google Scholar
• Sui M, Jiang X, Chen J, et al. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. Biomed Pharmacother. 2018;106:125–133.
   PubMed Web of Science ®Google Scholar
• Chen W, et al. Effect of magnesium isoglycyrrhizinate on the proliferation and oxidative stress of rat hepatic stellate cell in vitro. Chin J Hepatol. 2006;14:426–430.
   PubMedGoogle Scholar
• Wang Y, Zhang Z, Wang X, et al. Amelioration of ethanol-induced hepatitis by magnesium isoglycyrrhizinate through inhibition of neutrophil cell infiltration and oxidative damage. Mediators Inflamm. 2017;2017:3526903.
   PubMed Web of Science ®Google Scholar
• Zhao XJ, Yang YZ, Zheng YJ, et al. Magnesium isoglycyrrhizinate blocks fructose-induced hepatic NF-κB/NLRP3 inflammasome activation and lipid metabolism disorder. Eur J Pharmacol. 2017;809:141–150.
   PubMed Web of Science ®Google Scholar
• Xu S, Niu P, Chen K, et al. The liver protection of propylene glycol alginate sodium sulfate preconditioning against ischemia reperfusion injury: focusing MAPK pathway activity. Sci Rep. 2017;7:1–12.
   PubMed Web of Science ®Google Scholar
• Ren F, Zhou L, Zhang X, et al. Endoplasmic reticulum stress-activated glycogen synthase kinase 3β aggravates liver inflammation and hepatotoxicity in mice with acute liver failure. Inflammation. 2015;38:1151–1165.
   PubMed Web of Science ®Google Scholar
• Li Y, Tang Y, Wang S, et al. Endogenous n-3 polyunsaturated fatty acids attenuate T cell-mediated hepatitis via autophagy activation. Front Immunol. 2016;7:350.
   PubMed Web of Science ®Google Scholar
• Li J, Xia Y, Liu T, et al. Protective effects of astaxanthin on ConA-induced autoimmune hepatitis by the JNK/p-JNK pathway-mediated inhibition of autophagy and apoptosis. Plos One. 2015;10:e0120440.
   PubMed Web of Science ®Google Scholar
• Tee JK, Peng F, Tan YL, et al. Magnesium isoglycyrrhizinate ameliorates fibrosis and disrupts TGF-β-mediated SMAD pathway in activated hepatic stellate cell line LX2. Front Pharmacol. 2018;9:1018.
   PubMed Web of Science ®Google Scholar
• Tang G-H, Yang H-Y, Zhang J-C, et al. Magnesium isoglycyrrhizinate inhibits inflammatory response through STAT3 pathway to protect remnant liver function. World J Gastroenterol. 2015;21:12370–12380.
   PubMed Web of Science ®Google Scholar
• Wang W, Li X, Xu J, et al. Magnesium isoglycyrrhizinate attenuates D-galactosamine/lipopolysaccharides induced acute liver injury of rat via regulation of the p38-MAPK and NF-κB signaling pathways. Immunopharmacol Immunotoxicol. 2018;40:262–267.
   PubMed Web of Science ®Google Scholar
• Heymann F, Peusquens J, Ludwig-Portugall I, et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015;62:279–291.
   PubMed Web of Science ®Google Scholar
• Liu QGY. Concanavaline A induces immuno-damages of the liver in mice by triggering cell apoptosis. Chin J Immunol. 2008;24:876–878.
   Google Scholar
• Zhang NFY. Proliferation of human peripheral blood T lymphocytes stimulated by concanavalin A. Clin Med Eng. 2016;23:155–157.
   Google Scholar
• Bopeng ZJZY. Clinical study of magnesium isoglycyrrhizinate combined with ursodeoxycholic Acid in treatment of primary biliary cirrhosis. World Chin Med. 2017;12:289–292.
   Google Scholar
• Yang Q, Wang J, Liu R, et al. Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(-)CD69(+) subset proliferation. Drug Des Devel Ther. 2016;10:443–453.
   PubMed Web of Science ®Google Scholar
• Liu T, Xia Y, Li J, et al. Shikonin attenuates concanavalin A-induced acute liver injury in mice via inhibition of the JNK pathway. Mediators Inflamm. 2016;2016:2748367.
   PubMed Web of Science ®Google Scholar
• Xiao L, et al. Effect of curcumin on autoimmune hepatitis of mice induced by concanavalin A. Chin J Clin. 2010;4:734–738.
   Google Scholar
• Cheng Y, Zhang J, Shang J, et al. Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro. Pharmacology. 2009;84:183–190.
   PubMed Web of Science ®Google Scholar
• Jiang W, Liu J, Li P, et al. Magnesium isoglycyrrhizinate shows hepatoprotective effects in a cyclophosphamide-induced model of hepatic injury. Oncotarget. 2017;8:33252–33264.
   PubMedGoogle Scholar
• Qu B, Xing R, Wang H, et al. Multiple effects of magnesium isoglycyrrhizinate on the disposition of docetaxel in docetaxel-induced liver injury. Xenobiotica. 2017;47:290–296.
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhang Y, Song T, et al. Magnesium isoglycyrrhizinate ameliorates doxorubicin-induced acute cardiac and hepatic toxicity via anti-oxidant and anti-apoptotic mechanisms in mice. Exp Ther Med. 2018;15:1005–1012.
   PubMed Web of Science ®Google Scholar
• Wen Z, Lei Z, Yao L, et al. Circulating histones are major mediators of systemic inflammation and cellular injury in patients with acute liver failure. Cell Death Dis. 2016;7:e2391.
   PubMed Web of Science ®Google Scholar
• Li S, Xia Y, Chen K. Epigallocatechin-3-gallate attenuates apoptosis and autophagy in concanavalin A-induced hepatitis by inhibiting BNIP3. Drug Des Dev Ther. 2016;10:631–647.
   Google Scholar
• Liu FC, Lee HC, Liao CC, et al. Tropisetron protects against acetaminophen-induced liver injury via suppressing hepatic oxidative stress and modulating the activation of JNK/ERK MAPK pathways. Biomed Res Int. 2016;2016:1952947.
   PubMed Web of Science ®Google Scholar
• Hsu JT, Le PH, Lin CJ, et al. Mechanism of salutary effects of melatonin-mediated liver protection after trauma-hemorrhage: p38 MAPK-dependent iNOS/HIF-1α pathway. Am J Physiol Gastrointest Liver Physiol. 2017;312:G427–G433.
   PubMed Web of Science ®Google Scholar
• Peng Z, Gong X, Yang Y, et al. Hepatoprotective effect of quercetin against LPS/d-GalN induced acute liver injury in mice by inhibiting the IKK/NF-κB and MAPK signal pathways. Int Immunopharmacol. 2017;52:281–289.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen L, Zhang X, et al. Kaempferol protects mice from d-GalN/LPS-induced acute liver failure by regulating the ER stress-Grp78-CHOP signaling pathway. Biomed Pharmacother. 2019;111:468–475.
   PubMed Web of Science ®Google Scholar
• Zhao P, Xiao L, Peng J, et al. Exosomes derived from bone marrow mesenchymal stem cells improve osteoporosis through promoting osteoblast proliferation via MAPK pathway. Eur Rev Med Pharmacol Sci. 2018;22:3962–3970.
   PubMed Web of Science ®Google Scholar